Image pharmaphorum Editor Views & Analysis Deep Dive: Market Access It’s fair to say this is the most interesting time ever for market access. White Papers Sponsored A digital health roadmap for pharma, medical devices and ins... COVID-19 has massively accelerated the uptake of digital health technology across the whole ecosystem, with important implications for pharma, medical device and insurance tech companies. Views & Analysis Designing HCP engagement for the next normal Life sciences companies’ engagement with HCPs has changed significantly in the past 12 months, as the COVID-19 pandemic struck. Views & Analysis Global impact: How regulatory affairs is shaping development... When it comes to developing cutting-edge innovations, Astellas aims to be at the forefront. Load more results
Views & Analysis Deep Dive: Market Access It’s fair to say this is the most interesting time ever for market access.
White Papers Sponsored A digital health roadmap for pharma, medical devices and ins... COVID-19 has massively accelerated the uptake of digital health technology across the whole ecosystem, with important implications for pharma, medical device and insurance tech companies.
Views & Analysis Designing HCP engagement for the next normal Life sciences companies’ engagement with HCPs has changed significantly in the past 12 months, as the COVID-19 pandemic struck.
Views & Analysis Global impact: How regulatory affairs is shaping development... When it comes to developing cutting-edge innovations, Astellas aims to be at the forefront.
News Neurocrine pays $2.9bn for Soleno and extreme hunger drug Neurocrine Biosciences has agreed a $2.9bn deal to buy Soleno Therapeutics and its treatment for a rare, genetic form of severe obesity.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
